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Abstract: Several tetraoxane and 4-aminoquinoline molecules were prepared in 
order to examine the influence of ribofuranose as a carrier molecule on the an-
timalarial activity of test compounds. The synthesized compounds showed pro-
nounced antimalarial activity against Plasmodium falciparum chloroquine sus-
ceptible D6, chloroquine resistant W2 and multidrug-resistant TM91C235 (Thai-
land) strains. The aminoquinoline derivative 4 was more active against W2 and 
TM91C235 strains than the control compounds (CQ and MFQ). 
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INTRODUCTION 
Malaria is an infectious disease that affects more than 500 million people per 
annum, causing approximately two million deaths.1 It is most common in tropical 
and subtropical areas and 90 % of all cases are found in sub-Saharan Africa. 
Antimalarial drug resistance, particularly the widespread resistance of many Plas-
modium falciparum strains to most readily available drugs, such as chloroquine 
(CQ), hinders malaria control and is therefore a major public health problem. Re-
sistance to antimalarial drugs has increased the global cost of controlling the di-
sease. So far, no resistance to artemisinin (ART) or ART derivatives has been 
reported. Resistance, as well as the absence of a vaccine for protection against 
malaria causes an urgent need for new effective, safe and affordable drugs. 
Following previous results,2 new tetraoxanes and 4-aminoquinoline mole-
cules with ribofuranose as carrier molecules were synthesized. The synthesized 
tetraoxanes were screened in vitro against three P. falciparum strains: D6 (chloro-
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quine-susceptible), W2 (chloroquine-resistant), and TM91C235, a multidrug-resis-
tant strain. 
RESULTS AND DISCUSSION 
Chemistry 
Methyl 2,3-O-isopropylidene-D-ribofuranoside 2 was prepared from D-ri-
bose using a mixture of acetone/methanol and HCl (Scheme 1). Compound 2 was 
isolated in 64 % yield as a mixture of α- and β-anomers, and was pure enough to 
be used directly in the subsequent step. Oxidation using pyridinium chlorochro-
mate (PCC) afforded the aldehyde 3, which was further transformed into amine 4 
by reductive amination. Amine 4 was isolated as the salt 5 and after treatment 
with 1.0 % NaOH, the free amine was obtained. 
The synthesis of the tetraoxane derivative was accomplished starting from 
ester 6, which was hydrolyzed into acid 7 in 88 % yield, followed by further 
transformation via a mixed anhydride procedure into the corresponding ester 8 in 
82 % yield. 
 
Scheme 1. 
Antimalarial activity 
The synthesized compounds were screened in vitro against three P. falcipa-
rum strains: D6 (chloroquine and mefloquine (MFQ) susceptible strain), W2 (chlo-
roquine-resistant, MFQ susceptible), and TM91C235 (multidrug-resistant strain) 
following the protocol given in the literature (Table I).2b 
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TABLE I. In vitro antimalarial activities of tetraoxanes 4–8 against P. falciparum D6,a W2,b 
and TM91C235c strains 
IC50 / nM IC90 / nM Compound 
D6 W2 TM91C235 D6 W2 TM91C235 
4 40.37 141.35 58.25 72.77 232.96 134.45 
5 40.03 176.82 61.39 76.77 282.75 127.99 
8 115.97 599.23 701.38 405.63 1454.42 2286.79 
6 29.20 40.41 26.96 83.92 62.48 110.22 
MFQd 7.38 4.99 51.92 16.83 11.28 102.47 
CQd 13.62 371.65 178.07 19.89 662.35 391.42 
aP. falciparum African D6 clone; bP. falciparum Indochina W2 clone; cP. falciparum multidrug resistant TM91C23 
strain (Thailand); dcontrol compounds 
The synthesized aminoquinoline derivatives 4 and 5 had similar activity; the 
amine 4 was less active against P. falciparum strain D6 in comparison to the con-
trols CQ and MFQ. Compound 4 was 2.5−3 times more active than CQ against 
W2 and TM91C235 strains. 
On the other hand, the tetraoxane 8 was less active than CQ and MFQ, and 
significantly less active than the corresponding ester 6 against the three P. falci-
parum strains. According to these results, it is suggested that increased polarity 
of molecule, caused by hydrolysis of the isopropylidene and/or methoxy group in 
the in vitro test may be the cause of the observed small activity. Increasing the 
polarity of the molecules impedes their transport through biological membranes. 
In addition, the presence of hydroxy groups can cause facilitated secretion as a 
consequence of phase II metabolism. 
EXPERIMENTAL 
For general remarks, see references 2a, 2b, and 2c. 
ESI–MS spectra of the synthesized compounds were recorded on an Agilent Technologies 
6210 Time-of-Flight LC/MS instrument in the positive ion mode using CH3CN/H2O = 1/1 
with 0.20 % HCOOH as the carrying solvent solution. The samples were dissolved in pure 
acetonitrile (HPLC grade). The selected values were as follows: capillary voltage 4 kV; gas 
temperature 350 °C; drying gas 12 L min-1; nebulizer pressure 45 atm; fragmentator voltage: 
70 V. 
Methyl 2,3-O-isopropylidene-D-ribofuranoside,3 7,8,15,16-tetraoxadispiro[5.2.5.2]hexa-
decane-3-carboxylic acid,4 N1-(7-chloroquinolin-4-yl)-ethane-1,2-diamine5 were prepared ac-
cording to known procedures. 
N1-(7-Chloro-4-quinolinyl)-1,2-ethanediamine-N2-{[(3aS,4R,6aS)-6-methoxy-2,2- 
-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl]methyl} (4) 
Anhydrous CrO3 (1.02 g) was suspended in dry CH2Cl2 (25 mL) and pyridine (1.65 mL). 
The alcohol 2 (170 mg, 0.830 mmol) in anhydrous CH2Cl2 (2.0 mL) was added after 15 min 
into the resultant red solution and the reaction mixture was stirred for 20 min. Then the mix-
ture was poured onto cold saturated aqueous NaHCO3. The organic layer was separated and 
the aqueous layer was extracted with CH2Cl2 (2×20 mL). The combined organic layers were 
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dried (Na2SO4) and the solvent evaporated. The crude product was purified by dry-flash chro-
matography, eluent CH2Cl2, to afford the known6 aldehyde 3 (160 mg, 95.0 %). 
Sodium triacetoxyborohydride (168 mg, 0.790 mmol) was added to a mixture of alde-
hyde (80 mg, 0.39 mmol) and amine A (175 mg, 0.790 mmol) in CH2Cl2 (20 mL) and the 
reaction mixture was stirred at room temperature for 18 h. The reaction mixture was poured 
onto 1.0 % NaOH (20 mL) and extracted with CH2Cl2 (2×50 mL). The combined organic 
layers were dried over anh. Na2SO4 and evaporated to dryness. The crude product was purified 
by dry-flash chromatography, eluent EtOAc/MeOH = 9/1. Yield: 156 mg (98.0 %). Oil. 4: IR 
(KBr, cm-1): 3302w, 2936w, 2361w, 1611w, 1580s, 1535w, 1451m, 1371m, 1331w, 1274w, 
1239w, 1209m, 1158m, 1105s, 962m; 1H-NMR (200 MHz, CDCl3, δ / ppm): 8.52 (m, H–C(2')), 
7.95 (m, H–C(5')), 7.75 (m, H–C(8')), 7.34 (m, H–C(6')), 6.38 (m, H–C(3')), 5.92 (1H, bs), 
4.62 (2H, m), 4.33 (1H, m), 3.32 (5H, m), 3.06 (2H, m), 2.79 (2H, d), 1.97 (2H, bs), 1.49 (3H, 
s), 1.31 (3H, s); 13C-NMR (50 MHz, CDCl3, δ / ppm): 151.99, 149.87, 149.05, 134.83, 128.62, 
125.23, 121.28, 116.23, 112.47, 109.74, 99.16, 86.05, 85.30, 82.61, 55.15, 52.15, 47.12, 41.89, 
26.44, 24.87; (+)ESI–HRMS (m/z, %): 408.18229 ([M+H]+, 100); calculated 408.16845. 
(3aS,4R,6aS)-6-Methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl]methyl 
7,8,15,16-tetraoxadispiro[5.2.5.2]hexadecane-3-carboxylate (8) 
A solution of carboxylic acid 7 (120 mg, 0.440 mmol) in dry CH2Cl2 (15 mL) was stirred 
for 90 min at room temperature upon adding Et3N (61.4 µL, 0.440 mmol) and ClCO2Et (42.1 µL, 
0.440 mmol). Then a solution of alcohol 2 (90 mg, 0.44 mmol) in dry CH2Cl2 (5.0 mL) and a 
catalytic amount of DMAP (5.0 mg) were added. After 120 min, the reaction mixture was 
diluted with H2O, the layers were separated and the organic layer was washed with brine, 
dried over anh. Na2SO4 and evaporated to dryness. The crude product was purified by dry- 
-flash chromatography, eluent: hexane/EtOAc (9/1). Yield: 165 mg (82.0 %). Colorless foam, 
softening at 87−89 °C. IR (KBr, cm-1): 3441w, 2986m, 2939s, 2866m, 1737s, 1449m, 1381m, 
1318s, 1259m, 1194m, 1159m, 1094s, 1060s, 1016s, 944m, 926m. 1H-NMR (200 MHz, CDCl3, 
δ / ppm): 4.62 (2H, m), 4.36 (1H, m), 4.12 (2H, m), 3.31 (3H, m), 3.00–1.40 (20H, m), 1.48 
(3H, s), 1.32 (3H, s); 13C-NMR (50 MHz, CDCl3, δ / ppm): 174.12, 112.58, 109.34, 108.41, 
107.19, 85.14, 84.19, 81.75, 64.69, 54.88, 41.42, 29.44, 26.38, 25.27, 24.94, 21.99; (+)ESI– 
–HRMS (m/z, %): 481.20359 ([M+Na]+, 100); calculated 481.20442. 
In vitro antimalarial activity 
The in vitro antimalarial drug susceptibility screen is a modification of the procedures 
first published by Desjardins et al.,7 with modifications developed by Milhous et al.,8 and the 
details are given elsewhere.2a 
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У овом раду приказана је синтеза неколико рибофуранозидних тетраоксана и 4-амино-
хинолина у циљу сагледавања односа структура–активност ове врсте антималарика. Једи-
њења су показала изражену антималаријску активност према хлорокин-осетљивом (D6), хло-
рокин-резистентном (W2) и вишеструко резистентном (TM91C235 (Thailand)) соју Plasmo-
dium falciparum. Аминохинолински дериват 4 је активнији према W2 и TM91C235 сојевима 
од контролних једињења (хлорокин и мефлокин). 
(Примљено 13. фебруара 2008) 
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